Infliximab to treat Crohn's disease: An update

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 227-238

  Cottone, M ^a   Criscuoli, V ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Adult; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FETUS MALFORMATION; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); MONOTHERAPY; MYCOBACTERIOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; SPONTANEOUS ABORTION; TREATMENT OUTCOME;

EID: 80955139712     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S6440     Document Type: Review

References (64)

1. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997;159:6276-6282.
2. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut. 1996;39:684-689.
3. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009;3:77-97.
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology. 2007;132: 52-65.
5. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with Infliximab: A randomized trial. Ann Intern Med. 2007;146:829-838.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
7. Hanauer, SB, Feagan, BG, Lichtenstein, GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
8. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004;1: CD003574.
9. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficiency and safety of tumor necrosis factor antagonists in Crohn's disease: Meta- analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6: 644-653.
10. Ford A, Sandborn WJ, Khan KJ, et al. Efficency of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659.
11. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol. 2000;95: 3469-3477.
12. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterolog y. 1995;109:129-135.
13. D'haens G, Van Deventer S, Van Hogezand, R, et al. Endoscopic and his-tological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-1034.
14. Orlando A, Mocciaro F, Colombo E, et al. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005;37:577-583.
15. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fstulas in patients with Crohn's disease. N Engl J Med. 1999; 340:1398-1405.
16. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fstulizing Crohn's disease. N Engl J Med. 2004; 350:876-885.
17. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosono-graphic effect of ciprofoxacin on the treatment of perianal fstulae in Crohn's disease with Infliximab: A double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-1336.
18. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fstulating anal Crohn's disease. Colorectal Dis. 2005;7:164-168.
19. Guidi L, Ratto C, Semeraro S, et al. Combined therapy with infix-imab and seton drainage for perianal fstulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience. Tech Coloproctol. 2008;12:111-117.
20. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005;48:768-774.
21. Asteria CR, Ficari F, Bagnoli S, et al. Treatment of perianal fstulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: A pilot study. Scand J Gastroenterol. 2006;41:1064-1072.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance Infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
23. Feagan BG, Yan S, Bala M, et al. The effects of Infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98: 2232-2238.
24. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
25. Behm B W, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;1: CD006893.
26. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with Infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort. Gut. 2009;58:492-500.
27. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Inflix-imab maintenance treatment reduces hospitalizations, surgeries, and procedures in fstulizing Crohn's disease. Gastroenterology. 2005; 128:862-869.
28. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005;37:577-583.
29. Lémann M, Mary J Y, Duclos B, et al. Infliximab plus aza-thioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology. 2006;130: 1054-1061.
30. Colombel J F, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
31. Feagan B, McDonald JWD, Panaccione R, et al. A randomized trial of methotrexate in combination with Infliximab for the treatment of Crohn's disease. Gastroenterolog y. 2008;135:294-295.
32. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled Infliximab maintenance: A randomized trial. Gastroenterology. 2008;134:1861-1868.
33. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled Infliximab maintenance therapy. Gut. 2010;59: 1363-1368.
34. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with Infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort. Gut. 2009;58:492-500.
35. Ben-Horin S, Chowers Y. Review article: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33: 987-995.
36. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficiancy of Infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
37. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to Infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
38. Hanauer SB, Lichtenstein GR, Mayer L, et al. Extraintestinal manifestations of Crohn's disease: Response to Infliximab (Remicade) in the ACCENT I trial through 30 weeks. Am J Gastroenterol. 2001;96:A26.
39. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with Infliximab: A randomised controlled multicentre trial. Lancet. 2002;359:1187-1193.
40. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with Infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97:2688-2690.
41. Rispo A, Scarpa R, Di Girolamo E, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol. 2005;34:387-391.
42. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509.
43. Parsi MA, Achkar J P, Richardson S, et al. Predictors of response to Infliximab in patients with Crohn's disease. Gastroenterology. 2002;123:707-713.
44. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters infuencing the short-term outcome of anti-tumor necrosis factor (Infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.
45. Arnott ID, McNeill G, Satsangi J. An analysis of factors infuencing short-term and sustained response to Infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17:1451-1457.
46. Seksik P, Loftus E V, Beaugerie L, et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996. Gastroenterology. 2007;132:A17.
47. Weinberg AM, Rattan S, Lewis JD, et al. Strictures and response to infliximab in Crohn's disease. Am J Gastroenterol. 2002;97: S255.
48. Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol. 2010;16:2609-2615.
49. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2: CD008794.
50. Colombel J F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
51. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35.
52. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's disease patients treated with Infliximab: A long-term multicenter matched pair study. Infamm Bowel Dis. 2011;17:758-766.
53. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
54. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006;101:1030-1038.
55. D'Haens G, Baert F, van Assche G, et al. Early combined immu-nosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet. 2008; 371:660-667.
56. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
57. Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with Infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010;8:591-599.
58. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136: 441-450.
59. Yamamoto T, Umegae S, Matsumoto K. Impact of Infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: A prospective pilot study. Infamm Bowel Dis. 2009; 15:1460-1466.
60. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubin-sky MC. Case report: Evidence for transplacental transfer of maternally administered Infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-1258.
61. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving Infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.
62. D'Haens GR, Panaccione R, Higgins P, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
63. Orlando A, Armuzzi A, Papi C, et al. Clinical practice guidelines: The use of tumor necrosis factor-alpha antagonist therapy ininflammatory bowel disease. Dig Liver Dis. 2011;43:1-20.
64. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodu-lators, and Infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.